Cosmo Pharmaceuticals N.V Cash Flow Quality Index
Cosmo Pharmaceuticals N.V cash flow quality index. Cosmo Pharmaceuticals N.V (C43) has a Cash Flow Quality Index of 1.60x as of June 2022. Operating cash flow of €6.28 Million exceeds net income of €3.94 Million, indicating high earnings quality where cash backs reported profits. See Cosmo Pharmaceuticals N.V (C43) financial flexibility to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Cosmo Pharmaceuticals N.V (2016–2024)
Cash flow quality index of Cosmo Pharmaceuticals N.V from 2016 to 2024. Historical Cash Flow Quality Index for Cosmo Pharmaceuticals N.V across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore C43 cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cosmo Pharmaceuticals N.V Cash Flow Quality Index by Year (2016–2024)
Cosmo Pharmaceuticals N.V cash flow quality index by year from 2016 to 2024. Year-by-year earnings quality comparison for Cosmo Pharmaceuticals N.V. For the full cash flow conversion analysis, see Cosmo Pharmaceuticals N.V (C43) cash flow conversion.
| Year | Quality Index | Operating CF (EUR) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 1.22x | €162.41 Million | €133.24 Million | ▼ -95.8% |
| 2023 | 29.31x | €33.62 Million | €1.15 Million | ▲ +1419.7% |
| 2022 | 1.93x | €33.23 Million | €17.23 Million | ▲ +231.5% |
| 2021 | 0.58x | €12.61 Million | €21.67 Million | ▼ -48.1% |
| 2016 | 1.12x | €21.69 Million | €19.34 Million | — |